Blog
A 2024 meta analysis combines randomized trials of psilocybin for psychiatric disorders, estimating symptom changes and side effects under controlled care. We explain what it clarifies, where evidence is thin, and why legal and clinical safeguards matter.
Read article
A Scientific Reports clinical trial tests whether plasmapheresis can shift aging biomarkers and how safe the procedure is in this context. With key design details and results not yet public, we outline what surrogate endpoints can and cannot tell us.
Read article
A pilot randomized trial tested whether a short, multi component diet and lifestyle program could reduce epigenetic age estimated from DNA methylation. We explain what was done, why it matters, what changed, and the limits of the evidence.
Read article
A 2023 PubMed Central systematic review examines how testosterone relates to men's health, from sexual function to cardiovascular risk. We outline where the evidence is stronger or weaker, how to read lab results, and what remains uncertain.
Read article
An umbrella review of meta analyses of randomized trials evaluates psilocybin, MDMA, and other psychedelics for mental disorders. Signals of benefit appear in supervised clinical settings, but protocols differ and long‑term durability remains unclear.
Read article
Researchers report that a gene therapy designed to induce partial cellular reprogramming in naturally aged mice extended lifespan and shifted some molecular and tissue features toward a younger profile. We outline what was tested, why it matters, and the open questions.
Read article
How to pick blood biomarkers for geroscience trials? The TAME Workgroup proposes domain based panels (inflammation, stress response, mitochondrial/metabolic health) and clear criteria—analytic validity, clinical relevance, and sensitivity to change.
Read article
A small randomized pilot trial explored whether a structured diet and lifestyle program could shift DNA methylation–based epigenetic age. Early signals suggest change is possible, but findings are preliminary and require larger, longer, independent trials.
Read article
Nature Biotechnology reports the FDA has cleared a first‑in‑human Phase 1 trial of a cellular rejuvenation therapy based on partial epigenetic reprogramming. This is a safety‑focused start, not proof of benefit or a market approval.
Read article
The TAME Biomarkers Workgroup offers a step by step framework for choosing blood based biomarkers in geroscience trials, clarifying context of use, analytic reliability, feasibility, and why multi marker panels often outperform single measures.
Read article
ClinicalTrials.gov record NCT07065955 outlines a planned study of a longevity‑oriented diet and a fasting‑mimicking diet. We summarize what the registry says, why it could matter for healthspan, and what to look for when results are reported.
Read article
An early randomized pilot study tested whether a structured diet and lifestyle program could shift DNA methylation–based epigenetic age. Results hint at short term improvement in this biomarker, but the trial was small, brief, and used a surrogate outcome.
Read article
A medRxiv protocol outlines FAXAge, a randomized controlled trial asking whether fasting and exercise can slow biological aging. We explain what protocols do and don’t show, how aging may be measured, and why rigorous methods matter.
Read article
A 2024 systematic review and meta analysis evaluated psilocybin assisted therapy for treatment‑resistant depression, summarizing benefits and risks observed in clinical trials while outlining important gaps in long‑term outcomes and generalizability.
Read article
Nature Biotechnology reports that the FDA has cleared a phase 1, first in human trial of a gene therapy aimed at cellular rejuvenation. This safety first study is the initial step toward testing aging related applications; no human efficacy data exist yet.
Read article
Can slowing aging pathways prevent many diseases at once? This review of geroscience outlines the promise, the need for new trial designs and regulation, and why biomarkers are not yet ready as surrogates—plus practical, cautious next steps.
Read article
A Biomolecules review details how AI could identify biological age biomarkers, personalize interventions, and respect oxidative stress signaling. It weighs evidence, flags batch effects and test–retest reliability, and urges careful, real‑world use.
Read article